Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.
Latest from Andrew McConaghie
CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.
Underwhelming efficacy led to the myostatin inhibitor's discontinuation of in SMA and FSHD, but Roche will continue a separate study in obesity. Meanwhile, Scholar Rock’s rival apitegromab could soon be back on track for approval.
The EU remains a major global player in biopharma but needs to act quickly or risk falling further behind its rivals, according to EFPIA.
The China-only result bodes well for Merck’s global studies, with Jefferies analysts convinced Sac-TMT will confirm superiority to TROP2 ADC competitors and more.
The company aims to restore near-normal muscle regrowth with its novel in vivo gene therapy PBGENE-MD, which it is now pursuing alone.
Now that CBER Director Vinay Prasad is leaving the FDA, Regenxbio's CEO is unsure a fast track pathway agreement will remain in place for its Duchenne muscular dystrophy gene therapy, RGX-202.